explore -WSS

explore

author：fashion 2025-09-28 04:58:59 - browse：498

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Why getting cancer drugs just got harder for rural patients

hotspot

focus

WSS

Flu vaccine offering decent levels of protection this winter, new data show

Live blog: Hearing on CRISPR

Why getting cancer drugs just got harder for rural patients

Key Senate panel to consider PBM, drug pricing reform package

Why getting cancer drugs just got harder for rural patients

Lung cancer screening guidelines updated for cigarette smokers

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Bright Health sells Medicare Advantage business to Molina

International team creates first chimeric human

How to save PrEP access — and even expand it

Life sciences investors close nearly $6 billion in new funds

Activists slam private health insurers over coverage restrictions

Key Senate panel to consider PBM, drug pricing reform package

How to save PrEP access — and even expand it

An inside look at PIPEs, biotech's buzzy new financing tool

Moonlake's readout produced a cash windfall. Risks remain

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

explore

How to convince healthy people to buy insurance

Prime Medicine says its gene editing passes test in monkeys

Prime Medicine says its gene editing passes test in monkeys

FDA does about

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Congress gives doctors Medicare pay bump

hotspot

focus

focus

explore